TITLE

Temazepam Clearance Unaltered in Cirrhosis

AUTHOR(S)
Greenblatt, David J.; Verburg-Ochs, Birgitt; Matlis, Rita; Ochs, Hermann R.
PUB. DATE
January 1986
SOURCE
American Journal of Gastroenterology;Jan1986, Vol. 81 Issue 1, p80
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The kinetics of a single oral dose of the benzodiazepine hypnotic temazepam was evaluated in nine patients with biopsy-proven cirrhosis and in seven healthy controls matched for age and sex. Peak serum temazepam concentrations were reached later in cirrhotics than in controls (2.9 versus 0.6 h after dosage; p < 11.05), indicating slower temazepam absorption in patients with cirrhosis. Temazepam volume of distribution was smaller in cirrhotics compared to controls, and elimination half-life shorter (10.6 versus 14.6 h). However, these differences were not significant. There were no significant differences between cirrhotics and controls in clearance of total temazepam (1.03 versus 1.03 ml/min/kg), clearance of unbound temazepam (27 versus 31 ml/min/kg), or free fraction in serum (3.9 versus 3.5% unbound). In two cirrhotic patients who received 20 mg of temazepam daily for 8 days, the extent of accumulation was consistent with the dosage interval relative to the elimination half-life, and was similar to the accumulation profile in healthy volunteers. Thus the onset of temazepam hypnotic activity may he delayed in cirrhotic patients, but the rate of elimination and the extent of accumulation are not altered compared to healthy persons of similar age and sex.
ACCESSION #
16224503

 

Related Articles

  • Serum Apolipoprotein(a) Concentrations and Apo(a) Phenotypes in Patients With Liver Cirrhosis. Ciccarese, Milco; Tonolo, Giancarlo; Brizzi, Patrizia; Secchi, Giannina; Garrucciu, Giovanni; Spanedda, Mario; Salis, Salvatore; Calvia, Pierangela; Asara, Angela; Fung Ki Wong; Maioli, Mario; Realdi, Giuseppe // American Journal of Gastroenterology;Sep1998, Vol. 93 Issue 9, p1505 

    Objective: The liver is the major site of apolipoprotein(a) synthesis, and an inverse correlation between the size of apolipoprotein(a) isoforms and its serum levels have been described. We evaluated the Apo(a) serum levels and its isoforms in patients with liver cirrhosis at different stages of...

  • Prescribing Medications in Patients with Decompensated Liver Cirrhosis. Amarapurkar, Deepak N. // International Journal of Hepatology;2011, p1 

    Patients with decompensated liver cirrhosis have various serious complications which require multiple drugs for therapeutic or prophylactic use. Majority of the drugs are primarily metabolized and excreted by hepatobiliary system; hence, liver cell necrosis contributes to impaired drug handling...

  • Efficacy of High-Dose Intra-dermal Hepatitis B Virus Vaccine in Previous Vaccination Non-responders with Chronic Liver Disease. Dhillon, S.; Moore, C.; Li, S.; Aziz, A.; Kakar, A.; Dosanjh, A.; Beesla, A.; Murphy, L.; Thiel, D. // Digestive Diseases & Sciences;Jan2012, Vol. 57 Issue 1, p215 

    Background: Hepatitis B virus (HBV) vaccination is essential in chronic liver disease (CLD), because it can help prevent acute-on-chronic disease, which has potentially fatal complications. Unfortunately, this group has a significant proportion of HBV vaccination non-responders. A variety of...

  • Liver cirrhosis.  // Nursing Standard;11/22/2006, Vol. 21 Issue 11, p58 

    A quiz concerning liver cirrhosis is presented.

  • Liver cirrhosis: lobar differences in disease progression and carcinogenesis. Sakon, Masato // Journal of Gastroenterology;2000, Vol. 35 Issue 6, p479 

    Comments on a study by S. Arjizumi et al on lobar differences in liver disease progression and carcinogenesis. Factors that influence differences in progression of liver cirrhosis among liver segments; Segment where hepatocellular carcinoma occurs frequently; Role of blood flow in hypertrophy...

  • Type 1 diabetes associated with chronic liver disease. Taliercio, Adam // Endocrine Today;Dec2012, Vol. 10 Issue 12, p11 

    The article explores a study on patient with type 1 diabetes' greater risk for developing chronic liver disease, which was concluded by the researchers after they found that 14 type 1 diabetes patients in their study developed cirrhosis.

  • Liver I.  // Gut;Jun2014 Supplement, Vol. 63, pA87 

    The article presents abstracts on studies done on liver diseases on topics including reduced amount of serum sodium in patients treated with terlipressin, care in decompensated cirrhosis, and management of patients with decompensated liver disease.

  • Diagnostic Accuracy of Serum Hyaluronic Acid, FIBRO Spect II, and YKL-40 for Discriminating Fibrosis Stages in Chronic Hepatitis C. Mehta, Preeti; Ploutz-Snyder, Robert; Nandi, Jyotirmoy; Rawlins, Sekou R.; Sanderson, Schuyler O.; Levine, Robert A. // American Journal of Gastroenterology;Apr2008, Vol. 103 Issue 4, p928 

    OBJECTIVES: Noninvasive serum markers of liver fibrosis are being used as an alternative to liver biopsy. Currently available tests distinguish, with accuracy, only absent/minimal fibrosis (Ishak stages 0–1) and advanced fibrosis/cirrhosis (Ishak stages 4–6), but not intermediate...

  • SERUM γ-GLUTAMYL-TRANSPEPTIDASE ISOFORMS IN ALCOHOLIC LIVER DISEASE. BELLINI, MASSIMO; TUMINO, EMANUELE; GIORDANI, ROBERTO; FABRINI, GIANCARLO; COSTA, FRANCESCO; GALUI, RENATO; RUCCO, MARCELLA; BELCARI, CLAUDIO; MICHELASSI, CLAUDIO; MURRI, LUIGI; MALTINTI, GIACOMO; MARCHI, SANTINO // Alcohol & Alcoholism;May1997, Vol. 32 Issue 3, p259 

    γ-Glutamyltranspeptidase (γGT) appears in serum in multiple forms; their significance and clinical utility in hepatobiliary and pancreatic diseases are still a matter of controversy. Electrophoretic separation of the multiple forms of γGT on agarose gel was performed in 20 alcoholic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics